Novo Nordisk announces that both subcutaneous and oral amycretin advances to Phase III for weight management after positive regulatory feedback. Amycretin, a GLP-1 and amylin receptor agonist, showed promising results in previous studies. The Phase III program is planned to start in Q1 2026 for adults with overweight or obesity.
- We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme, comments Martin Lange, EVP of Development.
